Risk Stratification of a Novel Noninvasive Fibrosis Score in Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Gastroenterology and Hepatology · 2026-10 · 24 (10) · 2732-2741
DOI: 10.1016/j.cgh.2026.01.035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-10. Verfasst von Johnny T K Cheung und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine and Primary Care, New Territories East Cluster, Hospital Authority, Hong Kong, China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Fatty Liver, Severity of Illness Index. Die Arbeit nennt 26 Literaturangaben. Gefördert von: The Chinese University of Hong Kong.
Abstract (Originalsprache)
BACKGROUND & AIMS: Risk stratification in metabolic dysfunction-associated steatotic liver disease (MASLD) may identify high-risk groups for early intervention to reduce liver-related complications. We examined the prognostic accuracy of the MAFLD fibrosis score (MFS) in predicting risks of liver-related events and mortality among patients with MASLD. METHODS: This prospective cohort study with a median follow-up period of 9.7 years included 683 patients with biopsy-proven MASLD at 2 tertiary centers in Malaysia and Hong Kong. Noninvasive scores, including MFS, were computed using routine clinical data. Cumulative incidences of any liver-related events and all-cause mortality were compared between patients at low (MFS
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Family Medicine and Primary Care, New Territories East Cluster, Hospital Authority, Hong Kong, China.
- Division of Gastroenterology and Hepatology, School of Medicine, Stanford University, Palo Alto, California.
- Department of Medicine and Therapeutics, Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong, China; State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese Unive…
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, China.
- Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
- Department of Pathology, Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia.
Förderung
- The Chinese University of Hong Kong
Zitieren
APA
Cheung, J. T. K., Zhang, X., Wong, G. L., Yip, T. C., Lin, H., Li, G., Leung, H. H., Lai, J. C., Mahadeva, S., Nik Mustapha, N. R., Wang, X. D., Liu, W. Y., Chan, W. K., Zheng, M. H., & Wong, V. W. (2026). Risk Stratification of a Novel Noninvasive Fibrosis Score in Metabolic Dysfunction-Associated Steatotic Liver Disease. Clinical Gastroenterology and Hepatology, 24(10), 2732-2741. https://doi.org/10.1016/j.cgh.2026.01.035
Vancouver
Cheung JTK, Zhang X, Wong GL, Yip TC, Lin H, Li G, et al. Risk Stratification of a Novel Noninvasive Fibrosis Score in Metabolic Dysfunction-Associated Steatotic Liver Disease. Clinical Gastroenterology and Hepatology. 2026;24(10):2732-2741. doi:10.1016/j.cgh.2026.01.035
BibTeX
@article{Cheung2026,
author = {Cheung, Johnny T K and Zhang, Xinrong and Wong, Grace Lai-Hung and Yip, Terry Cheuk-Fung and Lin, Huapeng and Li, Guanlin and Leung, Howard Ho-Wai and Lai, Jimmy Che-To and Mahadeva, Sanjiv and Nik Mustapha, Nik Raihan and Wang, Xiao-Dong and Liu, Wen-Yue and Chan, Wah-Kheong and Zheng, Ming-Hua and Wong, Vincent Wai-Sun},
title = {Risk Stratification of a Novel Noninvasive Fibrosis Score in Metabolic Dysfunction-Associated Steatotic Liver Disease},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {10},
pages = {2732--2741},
doi = {10.1016/j.cgh.2026.01.035}
}
EUVIMED